Skip to content

Johnson & Johnson Price, Chart & Factor Exposure

Free Data & Analytics Access

Latest earnings: October 13, 2026 results vs estimates

Johnson & Johnson · E.JNJ.NYSE · United States
Use symbol E.JNJ.NYSE in our API & Excel add-in to retrieve this data ↓
268.73
(+0.01%)
? Live Prices updated every 5-seconds. Momentum Factor ranges from -100 to +100 and is the mean of four timeframe signals (1 Day, 1 Week, 1 Month, 3 Months), where each timeframe is +1 if return is above 0 and -1 otherwise. Trend Factor ranges from -100 to +100 and is the mean of eight signals across 1-month, 3-months, 6-months, and 1-year, using price vs moving average and moving average slope (+1 or -1). A rollover occurs when trend flips sign. Bubble Risk is the z-score of current price vs 1-year price: (Current Price - 250 trading days SMA) / (250 days price standard deviation). Values above +2.5 indicate overbought; below -2.5 oversold. Realized Volatility (20-days) is the standard deviation of daily returns over the past 20 trading days multiplied by sqrt(252).
Momentum 100%
Trend 100%
Bubble Risk LOW
Realised Volatility (20D) 32.33%

Johnson & Johnson Forecast

Johnson & Johnson short-term momentum is strongly positive (up over 4 of 4 look-backs: 5, 10, 20 and 30 trading days), a short-term BUY signal. The long-term trend is strongly positive (8 of 8 checks up: price above, and slope of, its 50-, 100-, 150- and 200-day averages), a long-term BUY signal. Based on 20-day realised volatility of 32.3% a year, a typical one-standard-deviation range is 256.49–280.97 over a week, 243.65–293.81 over a month and 181.86–355.60 over a year. (Signals as of 1 Nov 2026.)

Johnson & Johnson Price Chart

MacroFinance.ai

Johnson & Johnson Factors

Test factors in Return analysis →
Market/MacroIndicatorNowChangeRange
Quantitative
Johnson & Johnson
Momentum (composite)
—
ⓘLatest reading of Momentum (composite).
Johnson & Johnson
Relative Volume (21d)
—
ⓘLatest reading of Relative Volume (21d).
Johnson & Johnson
Signal
0
ⓘLatest reading of Signal.
Fundamental
Valuation
Johnson & Johnson
P/E
40.88x
Stretched vs own history
QoQ +30.4%
YoY +107.4%
now 40.88319.52 low41.56 high
ⓘP/E As of 22 Nov 2026.See Johnson & Johnson returns when P/E looked like now →Opens Return analysis with the filter P/E within ±5% of today
Johnson & Johnson
P/S
6.62x
Stretched vs own history
QoQ −1.6%
YoY +23.3%
now 6.62425.32 low6.86 high
ⓘP/S As of 22 Nov 2026.See Johnson & Johnson returns when P/S looked like now →Opens Return analysis with the filter P/S within ±5% of today
Johnson & Johnson
P/B
8.07x
Stretched vs own history
QoQ +4.0%
YoY +29.2%
now 8.07096.19 low8.21 high
ⓘP/B As of 22 Nov 2026.See Johnson & Johnson returns when P/B looked like now →Opens Return analysis with the filter P/B within ±5% of today
Johnson & Johnson
EV/EBITDA
25.56x
Stretched vs own history
QoQ +25.4%
YoY +93.6%
now 25.564513.09 low25.97 high
ⓘEV/EBITDA As of 22 Nov 2026.See Johnson & Johnson returns when EV/EBITDA looked like now →Opens Return analysis with the filter EV/EBITDA within ±5% of today
Johnson & Johnson
EV/Sales
6.90x
Stretched vs own history
QoQ −1.7%
YoY +21.7%
now 6.90025.62 low7.15 high
ⓘEV/Sales As of 22 Nov 2026.See Johnson & Johnson returns when EV/Sales looked like now →Opens Return analysis with the filter EV/Sales within ±5% of today
Johnson & Johnson
FCF Yield
3.1%
Weak vs own history
QoQ −7.2%
YoY −20.9%
now 3.12912.76 low4 high
ⓘFCF Yield As of 22 Nov 2026.See Johnson & Johnson returns when FCF Yield looked like now →Opens Return analysis with the filter FCF Yield within ±5% of today
Johnson & Johnson
Earnings Yield
2.4%
Weak vs own history
QoQ −23.3%
YoY −51.8%
now 2.4462.41 low5.12 high
ⓘEarnings Yield As of 22 Nov 2026.See Johnson & Johnson returns when Earnings Yield looked like now →Opens Return analysis with the filter Earnings Yield within ±5% of today
Johnson & Johnson
Dividend Yield
1.9%
Weak vs own history
QoQ +1.0%
YoY −21.8%
now 1.93251.88 low2.49 high
ⓘDividend Yield As of 22 Nov 2026.See Johnson & Johnson returns when Dividend Yield looked like now →Opens Return analysis with the filter Dividend Yield within ±5% of today
Johnson & Johnson
Market Cap
$658.0B
Highest in 5 years
QoQ −0.2%
YoY +32.9%
now 658012.278490,407 low671,589 high
ⓘMarket Cap As of 22 Nov 2026.See Johnson & Johnson returns when Market Cap looked like now →Opens Return analysis with the filter Market Cap within ±5% of today
Balance-Sheet Health
Johnson & Johnson
Net Debt
$27.4B
Mid-range vs own history
QoQ −3.0%
YoY +0.7%
now 2742327,233 low32,936 high
ⓘNet Debt As of 22 Nov 2026.See Johnson & Johnson returns when Net Debt looked like now →Opens Return analysis with the filter Net Debt within ±5% of today
Johnson & Johnson
Net Debt / EBITDA
1.02x
High vs own history
QoQ +22.0%
YoY +48.6%
now 1.02280.68 low1.02 high
ⓘNet Debt / EBITDA As of 22 Nov 2026.See Johnson & Johnson returns when Net Debt / EBITDA looked like now →Opens Return analysis with the filter Net Debt / EBITDA within ±5% of today
Johnson & Johnson
Current Ratio
1.02x
Weak vs own history
QoQ −6.7%
YoY −5.4%
now 1.01611.02 low1.09 high
ⓘCurrent Ratio As of 22 Nov 2026.See Johnson & Johnson returns when Current Ratio looked like now →Opens Return analysis with the filter Current Ratio within ±5% of today
Johnson & Johnson
Quick Ratio
0.74x
Weak vs own history
QoQ −9.1%
YoY −7.1%
now 0.73880.74 low0.81 high
ⓘQuick Ratio As of 22 Nov 2026.See Johnson & Johnson returns when Quick Ratio looked like now →Opens Return analysis with the filter Quick Ratio within ±5% of today
Johnson & Johnson
Interest Coverage
19.03x
Weak vs own history
QoQ −25.9%
YoY −47.1%
now 19.025419.03 low35.98 high
ⓘInterest Coverage As of 22 Nov 2026.See Johnson & Johnson returns when Interest Coverage looked like now →Opens Return analysis with the filter Interest Coverage within ±5% of today
Johnson & Johnson
Debt / Equity
0.55x
Mid-range vs own history
QoQ −5.1%
YoY −5.2%
now 0.54770.55 low0.68 high
ⓘDebt / Equity As of 22 Nov 2026.See Johnson & Johnson returns when Debt / Equity looked like now →Opens Return analysis with the filter Debt / Equity within ±5% of today
Johnson & Johnson
Piotroski F-Score
5
Mid-range vs own history
QoQ −16.7%
YoY 0.0%
now 53 low6 high
ⓘPiotroski F-Score As of 22 Nov 2026.See Johnson & Johnson returns when Piotroski F-Score looked like now →Opens Return analysis with the filter Piotroski F-Score within ±5% of today
Johnson & Johnson
Altman Z-Score
5.42
Strong vs own history
QoQ −2.2%
YoY +11.0%
now 5.4224.8 low5.61 high
ⓘAltman Z-Score As of 22 Nov 2026.See Johnson & Johnson returns when Altman Z-Score looked like now →Opens Return analysis with the filter Altman Z-Score within ±5% of today
  19 members-only factors: Revenue Growth, Revenue CAGR 3Y, Earnings Growth, EBITDA Growth and moreSign up
Accounting Red Flags
  21 members-only factors: Sloan Accruals, Cash-Earnings Gap, Beneish M-Score, Days Sales in Receivables Index and moreSign up
Global Risk
  22 members-only factors: MacroFinance Risk Index, VIX, VSTOXX, VIX Term Structure and moreSign up
Teal = supportive for Johnson & Johnson, red = a headwind, grey = neutral. Hover or tap ⓘ for how each factor works and to see returns in similar conditions.

Johnson & Johnson fundamentals: income statement, balance sheet & cash flow

Johnson & Johnson reported revenue of $94.19bn and net income of $26.80bn in FY2025, the year ended 31 December 2025 — revenue up 6.0% and net income up 90.6% on the prior year. Free cash flow was $19.70bn. These figures are as reported in the filings, not restated: 41 fiscal years and 165 quarters of history, back to December 1985. 173 FINRA short-interest settlements are published alongside them, back to June 2019.

Revenue (FY2025)
$94.19bn
+6.0%
Net income
$26.80bn
+90.6%
Gross margin
67.88%
Free cash flow
$19.70bn
-0.7%
Net debt
$28.22bn
Shares short (30 Oct 2026)
17.07m
2.41 days to cover
Johnson & Johnson income statement, annual, as reported · USD billions unless stated
USD billionsFY2025FY2024FY2023FY2022FY2021
Period end31 Dec 202531 Dec 202431 Dec 202331 Dec 202231 Dec 2021
Revenue94.1988.8285.1679.9978.74
Cost of revenue30.2627.4726.7424.6023.40
Gross profit63.9461.3558.4155.3955.34
Research & development14.6717.2315.0514.1414.28
Selling, general & admin.23.68——20.2520.12
Operating income25.6022.1521.8521.0120.94
EBITDA41.0624.7829.3426.6126.75
Interest expense0.970.761.250.280.18
Pre-tax income32.5816.6915.0619.3619.18
Income tax5.782.621.742.991.38
Net income26.8014.0735.1517.9420.88

Download Johnson & Johnson fundamentals

Get the fundamentals as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_fundamentals&symbol=E.JNJ.NYSE&statement=all&freq=a&format=csv&years=10
DownloadLast 10 fiscal years, no login.
The free download stops at 10 fiscal years. A free account unlocks all 41 fiscal years and 165 quarters, the filing vintages behind each number and API access.
Create free account

Figures in USD, statements as filed and FINRA consolidated short interest. A cell is left blank where the filing does not report it or where the reported figure fails the statement’s own arithmetic. Short interest is the consolidated FINRA figure for the settlement date shown, published seven to eight business days later.

Research on Johnson & Johnson

Explore MacroFinance macro & markets research and analysis.

Browse all financial research →

Johnson & Johnson Trading Strategies

58 backtested tactical asset allocation strategies hold SPY (US market) or XLV (Health Care sector), the closest tradable exposure to Johnson & Johnson; 28 of them are invested now. Strategies currently invested are listed first.

Hypothetical backtests over each ETF's own history; past performance does not guarantee future results. Upgrade to see every strategy's allocation and performance.

From creators

See all 58 strategies holding SPY, XLV →

Statistical Distribution of Returns

Plus

How Johnson & Johnson’s returns are distributed — and how they change in a given market regime.

Regime filters

Market/Macro Indicator Criteria Value And (for Between) Action

No regime filter yet — the chart below shows every period. Add a factor condition, or pick a popular regime.

MacroFinance.ai
Full return statistics
Statistic All periods Matching
  Sharpe, maximum drawdown and the full percentile table are part of Plus. Unlock with Plus
Know how Johnson & Johnson behaves before the regime turns Plus unlocks the full return history, unlimited factor conditions, regime-versus-baseline statistics and export — on every market, stock, ETF and index.

About Johnson & Johnson (United States)

Johnson & Johnson is a listed security in the United States. This page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data (the last 10 years as CSV or JSON, no login).

Last updated: November 22, 2026

More on Johnson & Johnson

Frequently asked questions

What is Johnson & Johnson?
Johnson & Johnson is a listed security in the United States. On MacroFinance its page shows the latest price and daily change, a price chart, momentum, trend, bubble-risk and volatility signals, its factor exposures, the statistical distribution of its returns, the trading strategies that hold it and free historical data.
What is the latest Johnson & Johnson price?
The latest close is 268.73 (1 Nov 2026), +0.01% on the day. The price at the top of the page refreshes during the trading day.
Is Johnson & Johnson in an uptrend?
As of 1 Nov 2026, short-term momentum is strongly positive (4 of 4 look-backs up: 5, 10, 20 and 30 trading days) and the long-term trend is strongly positive (8 of 8 checks up on its 50- to 200-day moving averages). Bullish when both are positive, bearish when both are negative.
How volatile is Johnson & Johnson?
20-day realised volatility is 32.3% a year (1 Nov 2026), which implies a typical one-standard-deviation move of about 9.3% over a month and 4.6% over a week.
What factors affect Johnson & Johnson?
The Factors section lists the signals, relative-value, risk-model and macro factors linked to Johnson & Johnson, grouped as Quantitative Factors, Fundamental Factors, Accounting Red Flags, Global Risk Factors, each with its latest reading. Some factors are open to everyone; the rest need a MacroFinance plan.
Which trading strategies trade Johnson & Johnson?
58 backtested tactical asset allocation strategies trade Johnson & Johnson through SPY, XLV; 28 of them hold it now. The Trading Strategies section lists them with their current weight, CAGR, Sharpe ratio and maximum drawdown.
How are Johnson & Johnson returns analysed?
The Statistical Distribution of Returns section shows the distribution of Johnson & Johnson daily, weekly, monthly, 2-month and 3-month returns with count, annualised average return, volatility, Sharpe ratio and maximum drawdown, and lets you filter the history by factor conditions, e.g. only periods when momentum was positive. A free account tests up to 2 factor conditions over the last 1 year of history; a Plus plan unlocks the full history, unlimited conditions, the regime statistics and the export.
Where can I download free Johnson & Johnson historical data?
In the Free historical data section of this page: the last 10 years of Johnson & Johnson daily closes as CSV or JSON, no login needed. A free account unlocks the full history, Excel and API access.

Free Johnson & Johnson historical data (last 10 years)

Browse or instantly download the last 10 years of Johnson & Johnson daily price history. A free account unlocks the full history, an Excel export with factors, and API access.

Get the data as
https://macrofinance.ai/wp-admin/admin-ajax.php?action=mf_history&symbol=E.JNJ.NYSE&format=csv&years=10
DownloadLast 10 years, no login.
DateClose
2026-11-02270.56
2026-10-30273.2
2026-10-29275.2
2026-10-28271.04
2026-10-27268.73
2026-10-26266.3
2026-10-23263.81
2026-10-22267.61
2026-10-21257.78
2026-10-20259.36
Loading last 10 years…
The table and downloads stop at 10 years. A free account unlocks the full history, the Excel add-in and API access.
Create free account

About this stock

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.